Cell line · CVCL_1531
Papers54
1 to 20 of 54
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Cooperation between PRMT1 and PRMT6 drives lung cancer health disparities among Black/African American men. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. | NPJ Precis Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. | Pharmaceuticals (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1531/papers